Robinson Elliott sold 0 shares of HNGE (indirect holdings)

Robinson Elliott sold 0 indirectly-held shares of Hinge Health, Inc. (HNGE) on 2026-09-14.

Original reporting
SEC EDGAR · Robinson Elliott
Published Sep 16, 2026, 9:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 9:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HNGE
Neutral
high confidence
Mentioned
$HNGE
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HNGENeutralLow
01

Why it matters

The disclosed transaction involves no shares, so it carries no immediate market impact.

02

Market read

Trivial insider filing with no material effect on the stock.

03

What to watch

The filing confirms the director holds no position, which may affect future voting power considerations.

Relevance 2/10Novelty 2/10Timing: filed Sep 16 2026

Background

Form 4 disclosures are primary‑source filings that report insider transactions.

Company-level read

Ticker impact

$HNGENeutralHigh confidence
Context

Director Robinson Elliott filed a Form 4 showing a sale of 0 shares of Hinge Health.

Expected impact

none

Evidence & confidence

The transaction reports zero shares sold, indicating no material change in holdings.

Market effects

None; the filing does not affect the digital health sector.

None; limited to a single insider filing.

None

Counterpoint

Even a zero‑share filing could hint at future insider activity, but no concrete signal exists.

Key entities

  • Robinson Elliott

    Director of Hinge Health who filed the Form 4.

  • Hinge Health, Inc.

    Digital health company listed under ticker HNGE.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HNGEHighAI 8/10

Needham raises Hinge Health stock price target on client growth

Needham raised its price target for Hinge Health (NYSE:HNGE) to $135 from $115, citing strong client growth and quarterly performance. The company reported 28% year-over-year client growth, 50% revenue increase, and 154% stock return over six months. Q3 revenue was $235 million, up 52% year-over-year, with EPS of $0.66 beating estimates. Wells Fargo also raised its target to $132, noting strong margins and revenue growth.

$HNGEHighAI 8/10

Hinge Health (HNGE) Q3 2026 Earnings Call Transcript

Hinge Health (HNGE) reported Q3 2026 revenue of $235M, up 52% YoY, with gross margin at 88% and operating income at $77M. The company highlighted growth in its MSK, Migraine, and GI care programs, with strong early results in Migraine care. President Jim Pursley announced his departure at year-end to spend more time with family but will join the board.